RBM39 and leukemia: A recent study by Wang et al confirmed that RBM39 loss resulted in repressed cassette exon splicing and increased intron retention, and that spliceosome‐mutant leukemias showed preferential sensitivity to pharmacologic targeting of RBM39.138 These studies have raised the interesting possibility that spliceosome mutant leukemias may be sensitized to anticancer sulfonamide compounds, and is an interesting research area that may potentially motivate future clinical trials.